{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T20:45:39Z","timestamp":1788468339179,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81270610"],"award-info":[{"award-number":["81270610"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700122"],"award-info":[{"award-number":["81700122"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770203"],"award-info":[{"award-number":["81770203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070178"],"award-info":[{"award-number":["82070178"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["ZH19003"],"award-info":[{"award-number":["ZH19003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jtct.2022.03.018","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T20:40:07Z","timestamp":1647636007000},"page":"332.e1-332.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Optimal Active Anti-Thymocyte Globulin Exposure Associated with Minimum Risk of Virus Reactivation and Comparable Acute Graft-Versus-Host Disease Under Adult Myeloablative Haploidentical Peripheral Blood Stem Cell Transplantation"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7102-7521","authenticated-orcid":false,"given":"HaiTao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8480-5927","authenticated-orcid":false,"given":"YingXin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LiLi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JingJing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1764-4377","authenticated-orcid":false,"given":"JiShan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiangShu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SongHua","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoXiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LiPing","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DaiHong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.03.018_bib0001","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2217\/imt.15.128","article-title":"Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations","volume":"8","author":"Nishihori","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jtct.2022.03.018_bib0002","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-71-1-177","article-title":"Antilymphocytic antibody: effects in experimental animals and problems in human use","volume":"71","author":"Sell","year":"1969","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtct.2022.03.018_bib0003","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.bbmt.2014.11.676","article-title":"Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation","volume":"21","author":"Storek","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.018_bib0004","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4103\/ijmr.IJMR_752_19","article-title":"Anti-thymocyte globulin in haematology: recent developments","volume":"150","author":"Siddiqui","year":"2019","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.jtct.2022.03.018_bib0005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.03.018_bib0006","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.bbmt.2005.12.034","article-title":"Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation","volume":"12","author":"Bacigalupo","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.018_bib0007","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/blood-2013-05-502385","article-title":"Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome","volume":"123","author":"Lindemans","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.018_bib0008","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1083-8791(03)00127-7","article-title":"Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation","volume":"9","author":"Waller","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.018_bib0009","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/01.mph.0000184575.00717.25","article-title":"Antithymocyte globulin pharmacokinetics in pediatric patients after hematopoietic stem cell transplantation","volume":"27","author":"Seidel","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jtct.2022.03.018_bib0010","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/bloodadvances.2018030247","article-title":"Antirelapse effect of pretransplant exposure to rabbit antithymocyte globulin","volume":"3","author":"Dabas","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.03.018_bib0011","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S2352-3026(17)30029-7","article-title":"Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis","volume":"4","author":"Admiraal","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2022.03.018_bib0012","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bcmd.2009.02.005","article-title":"HLA-haploidentical blood and bone marrow transplantation with anti-thymocyte globulin: long-term comparison with HLA-identical sibling transplantation","volume":"43","author":"Chen","year":"2009","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.jtct.2022.03.018_bib0013","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/bmt.2011.250","article-title":"Patients receiving HLA-haploidentical\/partially matched related allo-HSCT can achieve desirable health-related QoL that is comparable to that of patients receiving HLA-identical sibling allo-HSCT","volume":"47","author":"Mo","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.018_bib0014","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2015-02-627786","article-title":"Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.018_bib0015","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1038\/leu.2016.110","article-title":"Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant","volume":"30","author":"Wang","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.03.018_bib0016","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/bmt.2013.191","article-title":"Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial","volume":"49","author":"Wang","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.018_bib0017","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/cncr.30540","article-title":"Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: long-term outcomes of a prospective randomized trial","volume":"123","author":"Chang","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.03.018_bib0018","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12916-019-1393-7","article-title":"Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study","volume":"17","author":"Lin","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.jtct.2022.03.018_bib0019","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1016\/j.scib.2021.06.002","article-title":"Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial","volume":"66","author":"Wang","year":"2021","journal-title":"Sci Bull"},{"key":"10.1016\/j.jtct.2022.03.018_bib0020","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bbmt.2008.11.027","article-title":"Total and active rabbit antithymocyte globulin (rATG;Thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation","volume":"15","author":"Call","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.018_bib0021","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(15)00045-9","article-title":"Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis","volume":"2","author":"Admiraal","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2022.03.018_bib0022","first-page":"931","article-title":"Rabbit-immunoglobulin G levels in patients receiving thymoglobulin as part of conditioning before unrelated donor stem cell transplantation","volume":"90","author":"Remberger","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.03.018_bib0023","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.trim.2012.06.003","article-title":"Effects of different serum-levels of ATG after unrelated donor umbilical cord blood transplantation","volume":"27","author":"Remberger","year":"2012","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.jtct.2022.03.018_bib0024","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/petr.12620","article-title":"Correlation of rabbit antithymocyte globulin serum levels and clinical outcomes in children who received hematopoietic stem cell transplantation from an alternative donor","volume":"20","author":"Elmahdi","year":"2016","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jtct.2022.03.018_bib0025","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bbmt.2010.02.027","article-title":"High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder","volume":"16","author":"Podgorny","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.018_bib0026","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/bmt.2011.166","article-title":"IgG antibodies to ATG early after pediatric hematopoietic SCT increase the risk of acute GVHD","volume":"47","author":"Jol-van der Zijde","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.018_bib0027","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bbmt.2018.12.065","article-title":"Rabbit antithymocyte globulin serum levels: factors impacting the levels and clinical outcomes impacted by the levels","volume":"25","author":"Jamani","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.018_bib0028","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.bbmt.2020.02.026","article-title":"Does lymphocyte count impact dosing of anti-thymocyte globulin in unrelated donor stem cell transplantation?","volume":"26","author":"Heelan","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.018_bib0029","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211063783","article-title":"Association between preconditioning absolute lymphocyte count and transplant outcomes in patients undergoing matched unrelated donor allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and anti-thymocyte globulin","volume":"12","author":"Seo","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jtct.2022.03.018_bib0030","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s00277-020-04156-6","article-title":"Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies","volume":"99","author":"Gao","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.03.018_bib0031","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/bjh.14331","article-title":"Similar incidence of severe acute GVHD and less severe chronic GVHD in PBSCT from unmanipulated, haploidentical donors compared with that from matched sibling donors for patients with haematological malignancies","volume":"176","author":"Li","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.03.018_bib0032","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1182\/blood.V98.10.2942","article-title":"Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO)","volume":"98","author":"Bacigalupo","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.018_bib0033","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.03.018_bib0034","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kroger","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.03.018_bib0035","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41409-020-0792-x","article-title":"Rabbit ATG\/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel","volume":"55","author":"Bonifazi","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.018_bib0036","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/bloodadvances.2016001560","article-title":"ATG in allogeneic stem cell transplantation: standard of care in 2017? Point","volume":"1","author":"Bacigalupo","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.03.018_bib0037","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.018_bib0038","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.bbmt.2015.04.025","article-title":"Post-transplantation cyclophosphamide and sirolimus after haploidentical hematopoietic stem cell transplantation using a treosulfan-based myeloablative conditioning and peripheral blood stem cells","volume":"21","author":"Cieri","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.018_bib0039","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.bbmt.2016.02.002","article-title":"Feasibility and outcome of haploidentical hematopoietic stem cell transplantation with post-transplant high-dose cyclophosphamide for children and adolescents with hematologic malignancies: an AIEOP-GITMO retrospective multicenter study","volume":"22","author":"Berger","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.018_bib0040","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1182\/bloodadvances.2016002386","article-title":"Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1","volume":"1","author":"Versluis","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.03.018_bib0041","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2018.189258","volume":"103","author":"Salvatore","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.03.018_bib0042","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/bmt.2015.108","article-title":"Long-term outcome of HLA-haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion based on an FBCA conditioning regimen for hematologic malignancies","volume":"50","author":"Lin","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.018_bib0043","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1182\/blood-2014-04-571570","article-title":"T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT","volume":"124","author":"Luo","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.018_bib0044","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1182\/blood-2012-08-453399","article-title":"Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies","volume":"121","author":"Di Bartolomeo","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.018_bib0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-017-0398-y","article-title":"Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant","volume":"10","author":"Xu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2022.03.018_bib0046","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00277-020-04317-7","article-title":"Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation","volume":"100","author":"Bailen","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.03.018_bib0047","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cncr.33255","volume":"127","author":"Battipaglia","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.03.018_bib0048","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bbmt.2014.05.029","article-title":"Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts","volume":"20","author":"Raiola","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.018_bib0049","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1038\/bmt.2015.93","article-title":"Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update","volume":"50","author":"Bacigalupo","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.018_bib0050","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.3324\/haematol.2016.149880","article-title":"Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide","volume":"101","author":"Goldsmith","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.03.018_bib0051","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","article-title":"Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning","volume":"19","author":"Raiola","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.018_bib0052","doi-asserted-by":"crossref","first-page":"e12629","DOI":"10.1111\/tid.12629","article-title":"Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation","volume":"19","author":"Slade","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2022.03.018_bib0053","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.hemonc.2018.11.002","article-title":"Epstein-Barr viremia and post-transplant lymphoproliferative disorders in patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide","volume":"12","author":"Mohyuddin","year":"2019","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.jtct.2022.03.018_bib0054","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3389\/fimmu.2019.00315","article-title":"Differential elimination of anti-thymocyte globulin of Fresenius and genzyme impacts T-cell reconstitution after hematopoietic stem cell transplantation","volume":"10","author":"Oostenbrink","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2022.03.018_bib0055","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood-2016-06-721936","article-title":"Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation","volume":"128","author":"Admiraal","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.018_bib0056","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s12185-016-1947-9","article-title":"Impact of low-dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation","volume":"103","author":"Kuriyama","year":"2016","journal-title":"Int J Hematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722011654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722011654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:01:52Z","timestamp":1763002912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722011654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2666636722011654"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.03.018","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal Active Anti-Thymocyte Globulin Exposure Associated with Minimum Risk of Virus Reactivation and Comparable Acute Graft-Versus-Host Disease Under Adult Myeloablative Haploidentical Peripheral Blood Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}